Endo submits response to US FDA for Fortesta
This article was originally published in Scrip
Endo Pharmaceuticals has submitted its response to the US FDA for the complete response letter it received in October for the NDA of Fortesta (testosterone 2% gel), a treatment candidate for men with hypogonadism (scripnews.com, 20 October 2009).
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.